On the Importance of Monitoring Both Transfection and Transduction Efficiencies in Cell Therapy Development

Development of biologics-based therapies continues at a rapid pace and will most likely increase, as our collective understanding expands. Specifically pertaining to cell-based therapies, monitoring genomic payloads of transfection vectors has evolved to become standard practice in producing consistent & predictable particles. And while several analytical techniques are available, numerous studies support specific advantages conferred by Analytical Ultra-Centrifugation (AUC) in measuring genomic load in populations of transfection vectors.

In contrast, often absent in many cell therapy workflows is direct monitoring of cell transduction efficiencies; phenotypic analyses are commonly used, but they often occur further downstream in the process. We present data demonstrating the Coulter Principle as a uniquely suitable platform for monitoring cell transduction efficiencies, doing so in a direct (e.g., non-labelling) manner. Taken together, these two platforms provide a more efficient means of controlling cell-based therapies.